Replies to post #97318 on NanoViricides Inc. (NNVC)

[Ubertino]

Nanoviricides® Anti-Ebola Results Presented at Annual Meeting of the American Society for Virology by USAMRIID Scientist

July 19, 2010 07:00 AM Eastern Daylight Time

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that the results of the evaluation of several of its nanoviricides® anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled “Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection.”

“Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection.”

The studies were performed in the laboratory of Dr. Gene Olinger at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD.

In cell culture screening assays, the nanoviricides® were evaluated for cytotoxicity and for inhibition of Ebola virus infection. Several of the nanoviricides demonstrated a dose-dependent inhibition of Ebola virus infectivity with no toxicity of uninfected cells at concentrations that were effective against the virus.

A subset of the nanoviricides that were effective in cell culture was selected for testing in vivo in a mouse model of Ebola infection. The compounds were well tolerated by the animals and showed some efficacy against the mouse-adapted Ebola virus. Efficacy of nanoviricides treatment against Ebola virus was demonstrated by an increase in lifespan in this uniformly 100% lethal animal model.

The Company developed a library of chemical ligands that were expected to bind to the Ebola virus envelope proteins. The results reported at this meeting will help guide the synthesis of next generation anti-Ebola nanoviricides in a lead optimization synthetic program. Optimized nanoviricides will also be evaluated against other similar Hemorrhagic Fever Viruses, e.g. Marburg virus.

Based on the current results and previous success with another hemorrhagic fever virus (viz. Dengue), the Company believes that it can develop a single nanoviricide drug that is highly effective against both Ebola and Marburg filoviruses. Developing a single drug against the various Ebola and Marburg viruses has been a major challenge for researchers in the field. Currently there are no approved vaccines or therapeutics for the prevention or treatment of Ebola and Marburg viruses.

Ebola/Marburg viruses are a major concern both as potential global health threats and as potential threat agents for Biosecurity and Biodefense, and are identified as Category A agents. Ebola outbreaks have resulted in fatality rates as high as 80% in humans (http://www.who.int/mediacentre/factsheets/fs103/en/index.html).

About USAMRIID:

USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense's Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID’s primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

http://www.businesswire.com/news/home/20100719005598/en/Nanoviricides%C2%AE-Anti-Ebola-Results-Presented-Annual-Meeting-American#.U_d0xvldUvg

[Rawnoc]

Nanopat: You clearly show that in '08 USAMRIID thought the results showed highly effective results in cell cultures, and then in '10 they were not as effective in mice.

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the broad-spectrum nanoviricides(TM) drug candidates were found to be highly effective against the deadly Ebola virus in initial cell culture studies by scientists at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

in '10: The compounds were well tolerated by the animals and showed some efficacy against the mouse-adapted Ebola virus.

The choice of highly and some is actually a scientific delineation. Sounds pretty imprecise I know.

They're going in the wrong direction. But let's talk more about EBOLA and not about TOx not being started, and the company not being able to determine how much material they can make in a week at the existing facility.

What will the next delay be?

Prediction: EBOLA is now such a big opportunity, they are using material that WAS going to be used for Flu Tox to EBOLA. This will be for "humanitarian" reasons and because it would be foolish not to take advantage of this current "crisis."